Phase 3 Clinical Trials With Primary Completion Dates in January 2024

This is a list of Phase 3 trials with primary completion dates in January 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2024-01-01 Phase 3 NCT04531982 Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
ALVR AlloVir, Inc. 2024-01-01 Phase 3 NCT05179057 Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
CING Cingulate Inc. 2024-01-01 Phase 3 NCT05924594 Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
MRNS Marinus Pharmaceuticals, Inc. 2024-01-01 Phase 3 NCT05323734 Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy